ClinicalTrials.gg
RecruitingNCT06881420Updated Oct 14, 2026

BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease

An observational study in Acute Ischemic Stroke and ICAS - Intracranial Atherosclerosis, sponsored by Fujian Medical University Union Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Fujian Medical University Union Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 14, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
100th of 188
500 · median 625
Started
2024
with 102 others
Observational
188 of 754
108 open now
Primary completion
2026-12
later than 153 of 399 live
Registered
531st of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 100th largest by planned enrollment of the 188 observational ones that give a count, is one of 103 that started in 2024, is one of 188 observational ones, reaches primary completion later than 153 of the 399 other live ones, and was the 531st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study will explore the safety and efficacy of BASIS technology in ICAS-LVO lesions through a multicenter, prospective, registry, observational single-arm study.By registering intraoperative recanalization using this technique time, recanalization grade, operative thrombectomy times, intraoperative complications perforating branch occlusion, vascular dissection, vascular rupture, Ectopic thrombus, probability of symptomatic intracranial hemorrhage, mRS Score and mortality rate were followed up for 3 months The unique advantages of the application of the assessment BASIS in this type of lesion provide new insights into complex lesions such as ICAS-LVO The thought and operation method can shorten the operation time, improve the good prognosis, reduce the economic burden and reduce the operation Complications make a positive contribution to ensure that patients receive safe, effective and precise treatment.

Read the detailed description

This project intends to set up a prospective multi-center single-arm study with no control group and no upper limit of cases.

Using BASIS (Balloon AngioplaSty with the dIstal protection of Stent retriever) technique .

- Balloon angioplasty under the protection of the remote thrombectomy stent for intravascular treatment, such as the BASIS technique for thrombectomy loss Failure, the surgeon can take different techniques for remedial treatment.

  1. Construct the three-axis system and establish the path. The microcatheter passes 15mm through the distal end of the thrombus Above, after the thrombectomy stent covering the narrow segment was released, angiography was performed to observe the stenosis and distal thrombus.
  2. Use the anchoring effect of the thrombectomy bracket to pull the microcatheter out of the body.
  3. Send the guide wire along the thrombectomy stent to the balloon expansion catheter, and place the balloon in the narrow section. At this time, follow the blood The position of the plug relative to the stenosis determines whether to semi-retrieve the Syphonet® plug holder, fill the balloon for expansion, Balloon pressure relief.
  4. Use the distal end of the thrombectomy stent to anchor and the support of the balloon dilating catheter to advance the thrombectomy catheter.

    Until the end of the thrombus suction catheter reaches the narrow site.

  5. Remove the balloon to enlarge the suction cavity and remove the thrombus using SWIM technique.
  6. The residual thrombus was cleaned up and the thrombectomy stent was released again. The thrombectomy stent was recovered after angiographic observation: assembled in vitro With the microcatheter, the thrombectomy stent was released again via the microcatheter. Angiography was performed to observe the treatment of thrombus and stenosis Avoid thrombus escape due to direct hand angiography, if there is still thrombus, continue mechanical thrombus removal until the thrombus is cleared After the microcatheter was recovered and the thrombectomy scaffold was withdrawn, the micro
03

Conditions studied

  • Acute Ischemic Stroke
  • ICAS - Intracranial Atherosclerosis

Keywords

  • Acute Ischemic Stroke
  • ICAS - Intracranial Atherosclerosis
  • Endovascular thrombectomy
  • BASIS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

ICAS-LAO stroke

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old;
  • Ischemic stroke;
  • Within 72 hours from the onset of symptoms to the time of visit, including post-awakening stroke or blindness For stroke patients, the time when symptoms start is defined as "the last normal time";
  • Neuroimaging examination indicated occlusion of anterior or posterior intracranial large vessels, TOAST type was large atherosclerosis type.
  • BASIS technique was used for intravascular therapy.

Exclusion criteria

Exclusion Criteria:

  • Neuroimaging findings on admission, acute occlusion of multiple vessels and tandem lesions;
  • History of atrial fibrillation or heart valve surgery;
  • There are clinical to the use of antiplatelet drugs (hemophilia or thrombocytopenia).Rare disease, known history of coagulation disorders, abnormalities; There is active internal bleeding, intracranial Bleeding history, arteriovenous malformation, aneurysm, etc.);
  • Other types of stroke, including hemorrhagic stroke.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • using BASIS technique

    Procedure: BASIS technique

Interventions

  • ProcedureBASIS technique

    Balloon AngioplaSty with the dIstal protection of Stent retriever

06

What researchers measure

Primary outcomes

  1. mRS scores at 90 days

    functional recovery, assessed by change in modified Rankin Scale (mRS) scores (ranging from 0 \[no symptoms\] to 6 \[death\]) at 90 days after onset

    Time frame: 90 days

  2. FPE:first pass effect

    Vascular revascularization rate by basis technique at the first attempt

    Time frame: From enrollment to the end of the surgery about 3 hours

Secondary outcomes

  1. Residual stenosis rate of target vessel

    Time frame: From enrollment to the end of the surgery about 3 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 35 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2025
First posted
Mar 18, 2025
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Dec 31, 2026was Dec 2025
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 31, 2026
Oct 14, 2026
Study completion
Dec 31, 2025→Dec 31, 2026
Oct 14, 2026
Enrollment
250→500
Oct 14, 2026
Title
A Prospective Multicenter Registry Study on BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Dec 31, 2025→Dec 31, 2026
    Study completion Dec 31, 2025→Dec 31, 2026
    Enrollment 250→500
    Title A Prospective Multicenter Registry Study on BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease
    + 4 other changes: index terms, verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06881420
Collaborators
Zhangzhou Municipal Hospital of Fujian Province, First Affiliated Hospital of Jinan University
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Jan 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion